- CureToday.com
- OncLive.com
- TargetedOnc.com
- CancerNetwork.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Dan Pollyea, MD, MS | Authors
Articles
Dan Pollyea, MD, MS, on Venetoclax and IDH Mutations in Patients With AML
January 21, 2021
The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.
Dan Pollyea, MD, MS, on the Discovery and Incidence of IDH1 and IDH2 mutations in Patients With AML
January 14, 2021
IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.
Daniel A. Pollyea, MD, on the Impact of Venetoclax in IDH-Mutant AML
December 30, 2020
The leukemia expert discussed the clinical implications of findings demonstrating improved response for patients with acute myeloid leukemia with IDH mutations.
Dan Pollyea, MD, on the Impact of Venetoclax in Patients With AML With IDH Mutations
December 24, 2020
Dan Pollyea, MD discusses the response rate and overall survival of venetoclax for patients with acute myeloid leukemia with IDH mutations.
Dan Pollyea, MD, Discusses Venetoclax For Patients With AML Harboring IDH Mutations
December 17, 2020
Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations